An FDG-avid lesion on a PET scan is an area of the body that absorbs a higher-than-normal amount of radioactive sugar (FDG) during the imaging test. This finding indicates increased metabolic activity in that tissue, which can be a sign of cancer, inflammation, or infection. The term “avid” simply means “eager” — the cells in that spot are taking up the sugar tracer more actively than the surrounding tissue.
How an FDG PET Scan Works
A PET scan uses a special camera to detect a radioactive tracer injected into your bloodstream. The tracer is attached to a sugar molecule called fluorodeoxyglucose (FDG). Because cancer cells and other highly active cells consume more sugar than normal cells, they pull more FDG out of the blood.
The scanner then creates images showing where the tracer collected. Areas with high uptake appear brighter on the scan. Radiologists describe these bright spots as “FDG-avid” when they are significantly more active than the background tissue around them.
The entire test typically takes about two hours from injection to scanning. The tracer needs time to circulate through your body and be absorbed by tissues before imaging begins.
What Does an FDG-Avid Finding Actually Indicate?
FDG avidity is not a diagnosis by itself. It is a metabolic signal that tells your doctor something is happening in that area. The most common causes of FDG avidity include:
- Cancer: Many malignant tumors have high glucose metabolism and appear FDG-avid.
- Inflammation: Active inflammatory conditions like rheumatoid arthritis or sarcoidosis can cause FDG uptake.
- Infection: Abscesses, pneumonia, or other infections attract white blood cells that consume glucose.
- Benign growths: Some non-cancerous tumors and nodules also take up FDG.
- Normal physiological activity: Certain organs and tissues naturally show FDG uptake, including the brain, heart, liver, and muscles that were recently used.
The location, intensity, and pattern of uptake help your doctor determine what the finding means. A single bright spot in a lymph node carries different implications than diffuse activity throughout an organ.
Is FDG Avidity Always Cancer?
No. This is one of the most important facts to understand about PET scans. Many non-cancerous conditions produce FDG-avid findings. Infections, autoimmune diseases, and even recent surgery or radiation therapy can cause increased glucose metabolism in tissue.
Research consistently shows that FDG PET scans have high sensitivity for detecting cancer — meaning they catch most tumors — but they are less specific. That means some benign conditions will also light up on the scan. These are called false positives in medical terminology.
Your doctor will interpret the FDG-avid finding in the context of your symptoms, other imaging tests, and sometimes a biopsy. A biopsy remains the only definitive way to confirm whether a suspicious area is cancer.
What Happens After an FDG-Avid Finding?
The next steps depend entirely on where the FDG-avid area is located and what your doctor suspects. Common follow-up approaches include:
- Correlation with other imaging: Your doctor may compare the PET scan with a CT or MRI to see the exact anatomy of the area.
- Biopsy: If the finding is suspicious and accessible, a tissue sample may be taken for pathological examination.
- Serial imaging: Sometimes the best approach is to repeat the scan after a period of time to see if the activity changes.
- Blood tests: Certain blood markers can provide additional information about whether cancer is present.
Do not attempt to interpret the significance of an FDG-avid finding on your own. The same scan result can mean very different things in different patients. A radiologist and your referring physician will put the result into context with your complete clinical picture.
What Is a Standardized Uptake Value (SUV)?
Radiologists use a number called the standardized uptake value (SUV) to measure how intense FDG uptake is in a particular area. Higher SUV numbers indicate more metabolic activity. The SUV is calculated by comparing the radioactivity in the lesion to the total dose injected and the patient’s body weight.
There is no single SUV cutoff that definitively separates cancer from benign conditions. In general, higher SUV values raise more concern, but some aggressive cancers can have relatively low SUV values, and some benign inflammatory conditions can have very high ones. The SUV is one piece of information among many.
Your doctor will also look at the shape and borders of the FDG-avid area. Irregular borders and certain patterns of uptake can be more concerning than smooth, well-defined areas.
Common Normal FDG Uptake Patterns
Some FDG uptake is completely normal and expected. The brain uses glucose as its primary fuel and always shows intense FDG activity. The heart muscle also takes up glucose, though the pattern varies depending on what you ate before the scan. The liver and spleen show moderate activity. Kidneys and bladder show activity because the tracer is excreted through the urinary system.
Muscles that were active before or during the scan can show FDG uptake. This is why patients are often asked to avoid exercise for 24 hours before the test and to remain still during the injection and waiting period. Tense neck muscles, talking, or chewing can all create FDG-avid areas that have nothing to do with disease.
Brown fat — a type of fat tissue that generates heat — can also take up FDG, especially in younger patients or in cold environments. This can create confusing findings that mimic disease.
Limitations of FDG PET Scans
FDG PET scans have real limitations that patients should understand. Small tumors below a certain size may not be detected. Some slow-growing cancers have low metabolic activity and may not appear FDG-avid at all. This is particularly true for certain types of prostate cancer, some kidney cancers, and low-grade lymphomas.
Blood sugar levels affect scan quality. Patients with diabetes or elevated blood glucose may have poor tracer uptake in tumors because the cells are competing with high sugar levels in the blood. This can lead to false-negative results. For this reason, patients are usually asked to fast for several hours before the scan.
Recent chemotherapy or radiation therapy can temporarily reduce FDG uptake in tumors, making them appear less active than they really are. Conversely, recent surgery or radiation can cause inflammation that increases FDG uptake in healthy tissue.
How to Prepare for an FDG PET Scan
Your doctor will give you specific instructions, but typical preparation includes fasting for 4 to 6 hours before the scan. You may drink water, but you should avoid sugary drinks, chewing gum, and food. You should also avoid strenuous exercise for at least 24 hours before the test.
Tell your doctor about all medications you take, including over-the-counter drugs and supplements. Some medications can interfere with the scan results. If you are pregnant, think you might be pregnant, or are breastfeeding, tell your doctor before scheduling the scan.
Wear comfortable clothing without metal fasteners. You may be asked to change into a hospital gown. Leave jewelry and other metal objects at home if possible.
Frequently Asked Questions
Does FDG avid always mean cancer?
No. Infections, inflammatory conditions, and normal physiological activity can all cause FDG avidity. A biopsy or additional testing is needed to confirm whether a finding is cancer.
What is a high SUV on a PET scan?
There is no universal cutoff, but higher SUV values generally indicate more metabolic activity and raise more concern. Your doctor interprets the SUV in context with the location, shape, and your clinical situation.
Can a PET scan be wrong?
Yes. PET scans can produce both false positives and false negatives. Some cancers do not take up FDG well, and some benign conditions appear FDG-avid. This is why PET results are always combined with other information.
How long does an FDG PET scan take?
The entire appointment usually lasts about two hours. The scan itself takes roughly 30 to 60 minutes after the tracer has circulated through your body.

